Literature DB >> 10189264

Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide transporter PepT1.

I Tamai1, T Nakanishi, H Nakahara, Y Sai, V Ganapathy, F H Leibach, A Tsuji.   

Abstract

In the present study, possible enhancement of intestinal absorption of L-dopa by utilizing intestinal peptide transporter was examined using Caco-2 cells and Xenopus oocytes expressing human peptide transporter (hPepT1). To see whether this peptide transporter could be utilized for the improvement of L-dopa absorption, we employed a dipeptide-mimetic derivative of L-dopa, L-dopa-L-Phe. L-Dopa-L-Phe inhibited the uptake of [14C]Gly-Sar, but not that of L-[3H]-dopa by Caco-2 cells. Uptake of L-dopa-L-Phe was increased by expression of hPepT1 in Xenopus oocytes. The appearance of L-dopa and its metabolite, dopamine, on the basolateral side of Caco-2 cells was significantly higher after addition of L-dopa-L-Phe than after that of L-dopa and was reduced by the presence of Gly-Sar on the apical side. These results indicate that the L-dopa-L-Phe is absorbed more efficiently than L-dopa and is taken up via the peptide transporter, but not via the amino acid transporter, demonstrating the possibility of targeting the peptide transporter as a means for improving intestinal absorption of peptide-like drugs.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10189264     DOI: 10.1021/js980186o

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

Review 1.  Theoretical predictions of drug absorption in drug discovery and development.

Authors:  Patric Stenberg; Christel A S Bergström; Kristina Luthman; Per Artursson
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Function, Regulation, and Pathophysiological Relevance of the POT Superfamily, Specifically PepT1 in Inflammatory Bowel Disease.

Authors:  Emilie Viennois; Adani Pujada; Jane Zen; Didier Merlin
Journal:  Compr Physiol       Date:  2018-03-25       Impact factor: 9.090

3.  Inhibition of intestinal dipeptide transport by the neuropeptide VIP is an anti-absorptive effect via the VPAC1 receptor in a human enterocyte-like cell line (Caco-2).

Authors:  Catriona M H Anderson; Maria E Mendoza; David J Kennedy; Demetrio Raldua; David T Thwaites
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

4.  Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes.

Authors:  Kaixun Li; Liya Xu; Ashutosh A Kulkarni; Daya I Perkins; Ian S Haworth; Daryl L Davies
Journal:  Alcohol Clin Exp Res       Date:  2008-03-11       Impact factor: 3.455

Review 5.  The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology.

Authors:  Hannelore Daniel; Gabor Kottra
Journal:  Pflugers Arch       Date:  2003-08-07       Impact factor: 3.657

6.  Mutation screening of two candidate genes from 13q32 in families affected with Bipolar disorder: human peptide transporter (SLC15A1) and human glypican5 (GPC5).

Authors:  Manjula Maheshwari; S L Christian; C Liu; J A Badner; S Detera-Wadleigh; E S Gershon; Richard A Gibbs
Journal:  BMC Genomics       Date:  2002-10-22       Impact factor: 3.969

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.